Front Line Genomics invites you to their event

Advances in Precision Oncology for Blood Cancers Webinar 2: Precision Medicine in Chronic Myeloid Leukaemia

About this event

Advances in Precision Oncology for Blood Cancers

Tuesdays the 6th, 13th and 20th of June at 3pm BST/ 4pm CET/ 10am EST

Cancer has emerged as the most prominent area in which genomics has made significant strides in the field of precision medicine. Blood cancers include a range of different diseases and remain the most common form of cancer in children. There is a clinical need to improve our ability to diagnose and treat blood cancers with highly effective drugs.

In this webinar series, we will highlight the trends that are paving the way for precision oncology in blood cancers with examples within specific disease areas. We will also showcase opportunities for the future, and how this will improve overall patient benefit. This webinar series will include a comprehensive review of blood cancers and the implementation of therapy and testing in the UK and abroad. By joining you will:

· Uncover the intricate interplay among genomics, biomarkers, immunotherapy and other cutting-edge techniques that are revolutionising the field of blood cancer treatment

· Discover the potential for future advancements and learn how they will enhance the overall benefit for patients

· Benefit from the invaluable insights from leading experts in the field to help propel your work forward.

**Please note that by registering for the first webinar in the series you will automatically gain access to all subsequent webinars. **

Webinar 2: Precision Medicine in Chronic Myeloid Leukaemia

Tuesday 13th of June at 3 pm BST/4 pm CET/10 am EST

Chronic myeloid leukaemia (CML) is a blood cancer characterised by a gradual growth rate that spans several years. When detected at an early stage the prognosis for a 5-year survival is generally favourable, and precision medicine presents novel possibilities for prolonging this life expectancy. This webinar will cover the advances in precision medicine for CML as well as their implementation in the clinic.

Talk title: Trends and Opportunities in the Treatment of CML

Gillian Horne, Clinical Senior Research Fellow, Paul O'Gorman Leukaemia Research Centre, University of Glasgow

Talk title: Clinical Diagnostic Testing in CML: Current Methods of Diagnosis and Management

Robert Dunn, Head of Cytogenetics, King's College Hospital Nhs Foundation Trust

Talk title: Updates on the Management of Chronic Myeloid Leukaemia

Fadi G. Haddad, Assistant Professor, The University of Texas MD Anderson Cancer Center

Webinar 3: Precision Medicine in Myeloproliferative Neuroplasms

Tuesday 20th of June at 3pm BST/ 4pm CET/ 10am EST

Myeloproliferative neoplasms (MPNs) encompass a collection of uncommon blood disorders. While officially categorised as blood cancers by the World Health Organization (WHO), individuals with MPNs frequently experience a relatively good state of well-being, and the prognosis may differ based on the rate of disease advancement. This webinar will explore the precision medicine and immunotherapy strategies available for addressing MPNs.

Talk Title: Momelotinib: The Case for a 4th JAK Inhibitor

Aaron T. Gerds, MD, Associate Professor of Medicine, Hematology & Medical Oncology, Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute

Talk Title: Tumor Antigen-Specific T-Cell Immunity in The Context Of Myeloproliferative Neoplasms

Cansu Cimen Bozkus, Assistant Professor, Icahn School of Medicine at Mount Sinai

Previous Webinars in the Series:

Webinar 1: Precision Medicine in Acute Myeloid Leukaemia

Tuesday 6th of June at 3pm BST/ 4pm CET/ 10am EST

Acute myeloid leukaemia (AML) is the predominant form of acute leukaemia among adults. It is characterised by rapid progression and necessitates prompt intervention. The webinar assesses the current state of precision medicine and immunotherapy in AML, emphasising avenues for enhancing diagnostic and treatment approaches. Moreover, it will highlight the advantages that patients can presently derive from these advancements as well as their potential future benefits.

Talk Title: New insights in NPM1-mutated AML

Brunangelo Falini, Head of the Institute of Hematology and Bone Marrow Transplantation, University and Hospital of Perugia

Talk Title: Selective Homing of CAR-CIK Cells to The Bone Marrow Niche Enhances Control of The Acute Myeloid Leukemia Burden

Andrea Biondi, Professor, University of Milano-Bicocca

This webinar series is kindly sponsored by QIAGEN

Hosted by

  • Guest speaker
    RD G
    Robert Dunn

  • Guest speaker
    GH G
    Gillian Horne

  • Guest speaker
    FH G
    Fadi Haddad

  • Team member
    Od T
    Ollie de Jong Front Line Genomics

Front Line Genomics

Delivering the Benefits of Genomics to Patients Faster

Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.